ELAN Hiring Alzheimers Strategic Marketing.Heres that Hiring Link as promised Bio ...........enjoy the Report https://sh.webhire.com/servlet/av/jd?ai=195&ji=2151932&sn=I
Job Title: Director/Senior Director, Strategic Marketing
Req #: elan-00001227
Location: Dublin DUB
Primary Objective:
The primary role of this key leadership position will be to provide a balance of both strategic marketing expertise, as well as, the requisite commercial operational support to prepare the company for its first new product launch in the International AD marketplace.
Duties and Responibilites:
-Partner with the VP's to develop and implement an innovative strategic sales and marketing plan designed to drive revenue for the company and build the requisite internal commercial infrastructure to support the upcoming launch of Élan's new AD product.
-Successfully design, build and implement a new commercial business model for Elan in Europe, from a people, systems and process perspective to address the unique challenges of launching a revolutionary, breakthrough therapy in AD marketplace.
-Develop, a comprehensive understanding of the global Alzheimer's marketplace, including an opportunity assessment which can serve as the basis for creation of Elan's major market strategy in AD.
-Work collaboratively with Elan commercial strategic marketing counterparts, as well as other key departments, to provide valuable commercial input, analytical support and strategic thought leadership on the future development of new products in Élan's AD portfolio.
-Formulate and execute a strategy to enhance Élan's position in the biopharmaceutical marketplace as the premier research and development organization in AD.
-Assume responsibility for directing and monitoring all third party contractors and vendors to ensure maximum ROI.
-Provide direction to field-based personnel to assure optimal customer interaction and seamless execution of communication programs.
-Ensure that the strategic marketing function has the highest level of visibility both internally, as well as with external corporate customers.
-Work collaboratively with human resources to recruit and manage a team of high performance marketing executives.
Minimum Education Required:
The successful candidate will ideally (but not exclusively) possess a post-graduate scientific degree or advanced business degree.
Minimum Experience Required:
-(S)He must have a previous track record of building a successful and strategic commercial organization from a people, systems and processes perspective.
-(S)He should have a minimum of ten years experience within a pharmaceutical or biotechnology organization along with an understanding of the competitive dynamics and of the ethical pharmaceutical industry, in major markets around the world.
-The person will bring a strong commercial orientation and will most likely have a career path that includes functional exposure to market research, strategic planning, product marketing, new product planning and life cycle or portfolio management.
-Additional experience in sales management, project management or product development early in his or her career would be a plus.
-This individual must have served in a senior leadership role (or as a number two) where they have previously assumed responsibility for new product planning and the subsequent launch of a breakthrough, revolutionary therapy.
-The ideal candidate will bring working knowledge of the competitive landscape and an understanding of the economic drivers, key customers and constituents, as well as, the marketing dynamics associated with the launch of a new product within the AD marketplace.
-This person should also bring a track record of successfully interfacing with R&D, as well as other key departments, on providing thought leadership and commercial input to both early and late stage development products.
Skills and Abilities:
The successful candidate will be a highly disciplined commercial operations executive within the pharmaceutical or biotechnology marketplace who has excellent quantitative and strategic thought leadership ability. (S)He will be business savvy, possess a strong commercial orientation and will be someone who works with a passion to deliver results. Other key personal characteristics required to be successful in this role include:
-Proven interpersonal and influence skills. This includes a demonstrated ability to use an open and supportive communication style and to work cross functionally, with multiple corporate sites and different personalities.
-Ability to think strategically including the ability to help define the future of Élan's AD product portfolio and make the appropriate economic and business decisions to get there.
-Solid business acumen and the ability to make decisions and complete tasks in an independent fashion.
-Excellent presentation skills and the ability to listen and communicate to a wide variety of scientific and commercially oriented individuals.
-Technical credibility, yet an innovative thinker who possesses strong project management capabilities and demonstrated experience in working well with multidisciplinary groups.
-Analytical and well reasoned in his/her thinking and have the ability take a position based on the integration of various input and reasoned analyses.
-Good energy level and a positive outlook and willingness to do what it takes to achieve personal and organizational goals.
-High degree of professionalism, ethics and honesty with the ability to serve as a credible and passionate champion for Élan's AD therapies.
---------------------------------------------------------------
---------------------------------------------------------------
OT..... a bit. Sector related. Disease related. Potential Market related. Disease Indication related. OK OK it's not off topic......
Hey Polak.....and ANYONE else interested. Let me know if you want the Morgan Stanley Report for Wyeth from Feb. 19/08 . It can be inboxed easily. The Report focuses on the Alzheimers aspect of Wyeths initiatives. Recall they are the 50% Partner to ELAN with AAB-001 the AD Drug that is currently Dosing in PHASElll while PHASEll is still not even completed. They Initiated the PHASElll from the Data from an 'INTERIM PEEK' of the PHASEll while keeping the Trial Blinded. Only about 8 people in the world have seen the PHASEll Interim Data which is slated to be revealed in July at the ICAD in Chicago. Only the FDA--EMEA--ELAN--Wyeth are privy. The Monitoring Committee is privy to the Safety Data.
This is similar to what Transition & ELAN may do although WYE/ELAN's drug no longer has the options AZD-103 has because of the APOE4 Carriers VE response and the resulting allowances made in the protocols going into Phaselll. In other words AZD-103/ELND005 can still catch up to AAB-001. Pretty much exactly like ELAN CEO Kelly Martin has said repeatedly.
Wyeth & ELAN's drug is very very different being a Biologic and not a Small Molecule but targets the same Amyloid-Beta Plaque that is described in Selkoes Amyloid Cascade much like AZD-103 does.......Dr. Cruz talks about it in Transitions Q2 Conference Call in response to a question from Peter (You'All) Johnson from Ashfield Capital Partners.
All in All a good read for those interested in the Alzheimers Valuations and Risks/Rewards......it also provides Different Case-Scenarios with the in-depth reasoning behind those Scenarios and resulting Share Price Impact.
GPP All